A 38-year-old woman is diagnosed with stage IB1 cervical cancer (tumor size 2.5 cm, no parametrial involvement) on biopsy. Before treatment planning, which investigation is most appropriate for staging and assessing distant metastases?

Explanation

## Staging Investigation for Early-Stage Cervical Cancer **Key Point:** Pelvic MRI with contrast is the imaging modality of choice for local staging of cervical cancer, assessing tumor size, parametrial involvement, and pelvic lymph node status. ### FIGO 2023 Staging Framework ```mermaid flowchart TD A[Cervical cancer diagnosed on biopsy]:::outcome --> B[Determine FIGO stage]:::action B --> C{Local staging assessment needed?}:::decision C -->|Yes| D[Pelvic MRI with contrast]:::action D --> E[Assess tumor size, parametrial invasion, vaginal/bladder involvement]:::outcome F{Distant metastases screening?}:::decision F -->|Yes| G[Chest imaging + abdominal imaging]:::action G --> H[CXR or CT chest; abdominal/pelvic imaging]:::outcome ``` ### Why Pelvic MRI for Local Staging? 1. **Superior soft tissue contrast** — Best visualization of cervical stroma, parametrium, and tumor margins. 2. **Parametrial invasion assessment** — Critical for distinguishing stage IB from IIA disease. 3. **Lymph node evaluation** — Detects pelvic lymph node enlargement (short axis >10 mm). 4. **Bladder/rectal involvement** — Identifies invasion into adjacent organs. 5. **No radiation exposure** — Safe for reproductive-age women. **High-Yield:** FIGO 2023 recommends pelvic MRI as the primary imaging modality for cervical cancer staging; PET-CT is reserved for advanced disease (stage IIB or higher) or suspected distant metastases [cite:FIGO 2023 Cervical Cancer Staging]. **Clinical Pearl:** In stage IB1 disease, pelvic MRI determines whether parametrial invasion is present—this distinction is crucial because parametrial involvement upgrades the disease to stage IIA and alters treatment (radiation + chemotherapy vs. surgery alone). ### Imaging Modalities Comparison | Modality | Indication | Limitation | |---|---|---| | **Pelvic MRI** | Local staging, parametrial assessment, early-stage disease | Cannot detect distant metastases; contraindicated with metallic implants | | **PET-CT** | Advanced/metastatic disease, nodal assessment in stage ≥IIB | Not first-line for early-stage; lower specificity for small lesions | | **CXR + Ultrasound** | Screening for distant metastases; resource-limited settings | Lower sensitivity for small lung/liver lesions; operator-dependent | | **Diagnostic laparoscopy** | Therapeutic staging (lymphadenectomy) in select cases | Invasive; not standard for diagnostic staging | ### Staging Workup Algorithm for Stage IB1 1. **Pelvic MRI** — Confirm stage, assess parametrial involvement. 2. **Chest X-ray** — Screen for pulmonary metastases. 3. **Abdominal ultrasound or CT** — Assess liver, para-aortic nodes (if MRI shows pelvic node involvement). 4. **Consider PET-CT** — Only if advanced features or high-risk factors present. **Mnemonic:** **STAMP** — **S**tage with **T**issue biopsy, **A**ssess with **M**RI, **P**lan treatment.